000129194 001__ 129194
000129194 005__ 20240228145549.0
000129194 0247_ $$2doi$$a10.1038/bmt.2017.119
000129194 0247_ $$2pmid$$apmid:28650448
000129194 0247_ $$2ISSN$$a0268-3369
000129194 0247_ $$2ISSN$$a0951-3078
000129194 0247_ $$2ISSN$$a1476-5365
000129194 0247_ $$2altmetric$$aaltmetric:21362612
000129194 037__ $$aDKFZ-2017-05199
000129194 041__ $$aeng
000129194 082__ $$a610
000129194 1001_ $$aZeisbrich, M.$$b0
000129194 245__ $$aTransplant-associated thrombotic microangiopathy is an endothelial complication associated with refractoriness of acute GvHD.
000129194 260__ $$aLondon$$bNature Publishing Group55086$$c2017
000129194 264_1 $$2Crossref$$3online$$bSpringer Science and Business Media LLC$$c2017-06-26
000129194 264_1 $$2Crossref$$3print$$bSpringer Science and Business Media LLC$$c2017-10-01
000129194 264_1 $$2Crossref$$3print$$bSpringer Science and Business Media LLC$$c2017-10-01
000129194 3367_ $$2DRIVER$$aarticle
000129194 3367_ $$2DataCite$$aOutput Types/Journal article
000129194 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1511266448_9859
000129194 3367_ $$2BibTeX$$aARTICLE
000129194 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000129194 3367_ $$00$$2EndNote$$aJournal Article
000129194 520__ $$aThere is increasing evidence that endothelial dysfunction is involved in refractoriness of acute GvHD (aGvHD). Here we investigated the hypothesis that another endothelial complication, transplant-associated thrombotic microangiopathy (TMA), contributes to the pathogenesis of aGvHD refractoriness. TMA was retrospectively assessed in 771 patients after allogeneic stem cell transplantation (alloSCT). Incidences of TMA and refractory aGvHD were correlated with biomarkers of endothelial damage obtained before alloSCT for patients receiving or not receiving statin-based endothelial prophylaxis (SEP). Diagnostic criteria for TMA and refractory aGvHD were met by 41 (5.3%) and 76 (10%) patients, respectively. TMA was overrepresented in patients with refractory aGvHD (45.0 vs 2.3% in all other patients, P<0.001). TMA independently increased mortality. Elevated pretransplant suppressor of tumorigenicity-2 and nitrates along with high-risk variants of the thrombomodulin gene were associated with increased risk of TMA. In contrast, SEP abolished the unfavorable outcome predicted by pretransplant biomarkers on TMA risk. Patients on SEP had a significantly lower risk of TMA (P=0.001) and refractory aGvHD (P=0.055) in a multivariate multistate model. Our data provide evidence that TMA contributes to the pathogenesis of aGvHD refractoriness. Patients with an increased TMA risk can be identified pretransplant and may benefit from pharmacological endothelium protection.
000129194 536__ $$0G:(DE-HGF)POF3-313$$a313 - Cancer risk factors and prevention (POF3-313)$$cPOF3-313$$fPOF III$$x0
000129194 542__ $$2Crossref$$i2017-06-26$$uhttps://www.springer.com/tdm
000129194 542__ $$2Crossref$$i2017-06-26$$uhttps://www.springer.com/tdm
000129194 588__ $$aDataset connected to CrossRef, PubMed,
000129194 7001_ $$0P:(DE-He78)ecb33fb615e08035fdcefcaebfdff8f0$$aBecker, Natalia$$b1$$udkfz
000129194 7001_ $$0P:(DE-He78)e15dfa1260625c69d6690a197392a994$$aBenner, A.$$b2$$udkfz
000129194 7001_ $$aRadujkovic, A.$$b3
000129194 7001_ $$aSchmitt, K.$$b4
000129194 7001_ $$aBeimler, J.$$b5
000129194 7001_ $$aHo, A. D.$$b6
000129194 7001_ $$aZeier, M.$$b7
000129194 7001_ $$aDreger, P.$$b8
000129194 7001_ $$aLuft, T.$$b9
000129194 77318 $$2Crossref$$3journal-article$$a10.1038/bmt.2017.119$$bSpringer Science and Business Media LLC$$d2017-06-26$$n10$$p1399-1405$$tBone Marrow Transplantation$$v52$$x0268-3369$$y2017
000129194 773__ $$0PERI:(DE-600)2004030-1$$a10.1038/bmt.2017.119$$gVol. 52, no. 10, p. 1399 - 1405$$n10$$p1399-1405$$tBone marrow transplantation$$v52$$x0268-3369$$y2017
000129194 909CO $$ooai:inrepo02.dkfz.de:129194$$pVDB
000129194 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)ecb33fb615e08035fdcefcaebfdff8f0$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000129194 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)e15dfa1260625c69d6690a197392a994$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000129194 9131_ $$0G:(DE-HGF)POF3-313$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vCancer risk factors and prevention$$x0
000129194 9141_ $$y2017
000129194 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000129194 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000129194 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bBONE MARROW TRANSPL : 2014
000129194 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000129194 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000129194 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000129194 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000129194 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000129194 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000129194 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000129194 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000129194 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5
000129194 9201_ $$0I:(DE-He78)C060-20160331$$kC060$$lBiostatistik$$x0
000129194 980__ $$ajournal
000129194 980__ $$aVDB
000129194 980__ $$aI:(DE-He78)C060-20160331
000129194 980__ $$aUNRESTRICTED
000129194 999C5 $$1JL Ferrara$$2Crossref$$9-- missing cx lookup --$$a10.1016/S0140-6736(09)60237-3$$p1550 -$$tLancet$$uFerrara JL, Levine JE, Reddy P, Holler E . Graft-versus-host disease. Lancet 2009; 373: 1550–1561.$$v373$$y2009
000129194 999C5 $$1JR Westin$$2Crossref$$9-- missing cx lookup --$$a10.1155/2011/601953$$p601953 -$$tAdv Hematol$$uWestin JR, Saliba RM, De Lima M, Alousi A, Hosing C, Qazilbash MH et al. Steroid-refractory acute GVHD: predictors and outcomes. Adv Hematol 2011; 2011: 601953.$$v2011$$y2011
000129194 999C5 $$1T Luft$$2Crossref$$9-- missing cx lookup --$$a10.1182/blood-2011-02-334821$$p1685 -$$tBlood$$uLuft T, Dietrich S, Falk C, Conzelmann M, Hess M, Benner A et al. Steroid-refractory GVHD: T-cell attack within a vulnerable endothelial system. Blood 2011; 118: 1685–1692.$$v118$$y2011
000129194 999C5 $$1S Dietrich$$2Crossref$$9-- missing cx lookup --$$a10.1016/j.bbmt.2012.09.018$$p22 -$$tBiol Blood Marrow Transplant$$uDietrich S, Falk CS, Benner A, Karamustafa S, Hahn E, Andrulis M et al. Endothelial vulnerability and endothelial damage are associated with risk of graft-versus-host disease and response to steroid treatment. Biol Blood Marrow Transplant 2013; 19: 22–27.$$v19$$y2013
000129194 999C5 $$1S Dietrich$$2Crossref$$9-- missing cx lookup --$$a10.3324/haematol.2013.090209$$p541 -$$tHaematologica$$uDietrich S, Okun JG, Schmidt K, Falk CS, Wagner AH, Karamustafa S et al. High pre-transplant serum nitrate levels predict risk of acute steroid-refractory graft-versus-host disease in the absence of statin therapy. Haematologica 2014; 99: 541–547.$$v99$$y2014
000129194 999C5 $$1SP Rachakonda$$2Crossref$$9-- missing cx lookup --$$a10.1200/JCO.2013.54.4056$$p3421 -$$tJ Clin Oncol$$uRachakonda SP, Penack O, Dietrich S, Blau O, Blau IW, Radujkovic A et al. Single-nucleotide polymorphisms within the thrombomodulin gene (THBD) predict mortality in patients with graft-versus-host disease. J Clin Oncol 2014; 32: 3421–3427.$$v32$$y2014
000129194 999C5 $$1JN George$$2Crossref$$9-- missing cx lookup --$$a10.1111/j.1537-2995.2004.00700.x$$p294 -$$tTransfusion$$uGeorge JN, Li X, McMinn JR, Terrell DR, Vesely SK, Selby GB . Thrombotic thrombocytopenic purpura-hemolytic uremic syndrome following allogeneic HPC transplantation: a diagnostic dilemma. Transfusion 2004; 44: 294–304.$$v44$$y2004
000129194 999C5 $$1S Changsirikulchai$$2Crossref$$9-- missing cx lookup --$$a10.2215/CJN.02070508$$p345 -$$tClin J Am Soc Nephrol$$uChangsirikulchai S, Myerson D, Guthrie KA, McDonald GB, Alpers CE, Hingorani SR . Renal thrombotic microangiopathy after hematopoietic cell transplant: role of GVHD in pathogenesis. Clin J Am Soc Nephrol 2009; 4: 345–353.$$v4$$y2009
000129194 999C5 $$1S Jodele$$2Crossref$$9-- missing cx lookup --$$a10.1016/j.blre.2014.11.001$$p191 -$$tBlood Rev$$uJodele S, Laskin BL, Dandoy CE, Myers KC, El-Bietar J, Davies SM et al. A new paradigm: diagnosis and management of HSCT-associated thrombotic microangiopathy as multi-system endothelial injury. Blood Rev 2015; 29: 191–204.$$v29$$y2015
000129194 999C5 $$1BL Laskin$$2Crossref$$9-- missing cx lookup --$$a10.1182/blood-2011-02-321315$$p1452 -$$tBlood$$uLaskin BL, Goebel J, Davies SM, Jodele S . Small vessels, big trouble in the kidneys and beyond: hematopoietic stem cell transplantation-associated thrombotic microangiopathy. Blood 2011; 118: 1452–1462.$$v118$$y2011
000129194 999C5 $$1MT Vander Lugt$$2Crossref$$9-- missing cx lookup --$$a10.1056/NEJMoa1213299$$p529 -$$tN Engl J Med$$uVander Lugt MT, Braun TM, Hanash S, Ritz J, Ho VT, Antin JH et al. ST2 as a marker for risk of therapy-resistant graft-versus-host disease and death. N Engl J Med 2013; 369: 529–539.$$v369$$y2013
000129194 999C5 $$1S Demyanets$$2Crossref$$9-- missing cx lookup --$$a10.1016/j.yjmcc.2013.03.020$$p16 -$$tJ Mol Cell Cardiol$$uDemyanets S, Kaun C, Pentz R, Krychtiuk KA, Rauscher S, Pfaffenberger S et al. Components of the interleukin-33/ST2 system are differentially expressed and regulated in human cardiac cells and in cells of the cardiac vasculature. J Mol Cell Cardiol 2013; 60: 16–26.$$v60$$y2013
000129194 999C5 $$1DA Pascual-Figal$$2Crossref$$9-- missing cx lookup --$$a10.1016/j.amjcard.2015.01.034$$p3B -$$tAm J Cardiol$$uPascual-Figal DA, Januzzi JL . The biology of ST2: the International ST2 Consensus Panel. Am J Cardiol 2015; 115 (7 Suppl): 3B–7B.$$v115$$y2015
000129194 999C5 $$1SJ Aldous$$2Crossref$$9-- missing cx lookup --$$a10.1016/j.cardfail.2012.01.008$$p304 -$$tJ Card Fail$$uAldous SJ, Richards AM, Troughton R, Than M . ST2 has diagnostic and prognostic utility for all-cause mortality and heart failure in patients presenting to the emergency department with chest pain. J Card Fail 2012; 18: 304–310.$$v18$$y2012
000129194 999C5 $$1DK Reichenbach$$2Crossref$$9-- missing cx lookup --$$a10.1182/blood-2014-10-606830$$p3183 -$$tBlood$$uReichenbach DK, Schwarze V, Matta BM, Tkachev V, Lieberknecht E, Liu Q et al. The IL-33/ST2 axis augments effector T-cell responses during acute GVHD. Blood 2015; 125: 3183–3192.$$v125$$y2015
000129194 999C5 $$1H Glucksberg$$2Crossref$$9-- missing cx lookup --$$a10.1097/00007890-197410000-00001$$p295 -$$tTransplantation$$uGlucksberg H, Storb R, Fefer A, Buckner CD, Neiman PE, Clift RA et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation 1974; 18: 295–304.$$v18$$y1974
000129194 999C5 $$1A Rovo$$2Crossref$$9-- missing cx lookup --$$a10.1053/j.seminhematol.2011.10.001$$p25 -$$tSemin Hematol$$uRovo A, Tichelli A, Late Effects Working Party of the European Group for B, Marrow T . Cardiovascular complications in long-term survivors after allogeneic hematopoietic stem cell transplantation. Semin Hematol 2012; 49: 25–34.$$v49$$y2012
000129194 999C5 $$1DK Cheuk$$2Crossref$$uCheuk DK, Chiang AK, Ha SY, Chan GC . Interventions for prophylaxis of hepatic veno-occlusive disease in people undergoing haematopoietic stem cell transplantation. Cochrane Database Syst Rev 2015; 5: CD009311.$$y2015
000129194 999C5 $$1VT Ho$$2Crossref$$9-- missing cx lookup --$$a10.1016/j.bbmt.2005.06.001$$p571 -$$tBiol Blood Marrow Transplant$$uHo VT, Cutler C, Carter S, Martin P, Adams R, Horowitz M et al. Blood and marrow transplant clinical trials network toxicity committee consensus summary: thrombotic microangiopathy after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2005; 11: 571–575.$$v11$$y2005
000129194 999C5 $$1T Ruutu$$2Crossref$$9-- missing cx lookup --$$a10.3324/haematol.10699$$p95 -$$tHaematologica$$uRuutu T, Barosi G, Benjamin RJ, Clark RE, George JN, Gratwohl A et al. Diagnostic criteria for hematopoietic stem cell transplant-associated microangiopathy: results of a consensus process by an International Working Group. Haematologica 2007; 92: 95–100.$$v92$$y2007
000129194 999C5 $$1National Kidney F$$2Crossref$$uNational Kidney F. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002; 39 (2 Suppl 1): S1–266.$$y2002
000129194 999C5 $$1R Simon$$2Crossref$$9-- missing cx lookup --$$a10.1002/sim.4780030106$$p35 -$$tStat Med$$uSimon R, Makuch RW . A non-parametric graphical representation of the relationship between survival and the occurrence of an event: application to responder versus non-responder bias. Stat Med 1984; 3: 35–44.$$v3$$y1984
000129194 999C5 $$1PM Grambsch$$2Crossref$$9-- missing cx lookup --$$a10.2307/2533277$$p1469 -$$tBiometrics$$uGrambsch PM, Therneau TM, Fleming TR . Diagnostic plots to reveal functional form for covariates in multiplicative intensity models. Biometrics 1995; 51: 1469–1482.$$v51$$y1995
000129194 999C5 $$1H Putter$$2Crossref$$9-- missing cx lookup --$$a10.1002/sim.2712$$p2389 -$$tStat Med$$uPutter H, Fiocco M, Geskus RB . Tutorial in biostatistics: competing risks and multi-state models. Stat Med 2007; 26: 2389–2430.$$v26$$y2007
000129194 999C5 $$1N Holländer$$2Crossref$$9-- missing cx lookup --$$a10.1002/sim.1611$$p1701 -$$tStat Med$$uHolländer N, Sauerbrei W, Schumacher M . Confidence intervals for the effect of a prognostic factor after selection of an 'optimal' cutpoint. Stat Med 2004; 23: 1701–1713.$$v23$$y2004
000129194 999C5 $$1F Peyvandi$$2Crossref$$9-- missing cx lookup --$$a10.1111/j.1365-2141.2006.06126.x$$p187 -$$tBr J Haematol$$uPeyvandi F, Siboni SM, Lambertenghi Deliliers D, Lavoretano S, De Fazio N, Moroni B et al. Prospective study on the behaviour of the metalloprotease ADAMTS13 and of von Willebrand factor after bone marrow transplantation. Br J Haematol 2006; 134: 187–195.$$v134$$y2006
000129194 999C5 $$1O Elsallabi$$2Crossref$$9-- missing cx lookup --$$a10.1177/1076029615598221$$p12 -$$tClin Appl Thromb Hemost$$uElsallabi O, Bhatt VR, Dhakal P, Foster KW, Tendulkar KK . Hematopoietic stem cell transplant-associated thrombotic microangiopathy. Clin Appl Thromb Hemost 2016; 22: 12–20.$$v22$$y2016
000129194 999C5 $$1Y Inamoto$$2Crossref$$9-- missing cx lookup --$$a10.1038/bmt.2008.419$$p43 -$$tBone Marrow Transplant$$uInamoto Y, Ito M, Suzuki R, Nishida T, Iida H, Kohno A et al. Clinicopathological manifestations and treatment of intestinal transplant-associated microangiopathy. Bone Marrow Transplant 2009; 44: 43–49.$$v44$$y2009
000129194 999C5 $$1T Nishida$$2Crossref$$9-- missing cx lookup --$$a10.1038/sj.bmt.1704512$$p1143 -$$tBone Marrow Transplant$$uNishida T, Hamaguchi M, Hirabayashi N, Haneda M, Terakura S, Atsuta Y et al. Intestinal thrombotic microangiopathy after allogeneic bone marrow transplantation: a clinical imitator of acute enteric graft-versus-host disease. Bone Marrow Transplant 2004; 33: 1143–1150.$$v33$$y2004
000129194 999C5 $$1J Chapin$$2Crossref$$uChapin J, Shore T, Forsberg P, Desman G, Van Besien K, Laurence J . Hematopoietic transplant-associated thrombotic microangiopathy: case report and review of diagnosis and treatments. Clin Adv Hematol Oncol 2014; 12: 565–573.$$y2014
000129194 999C5 $$1ED Batts$$2Crossref$$9-- missing cx lookup --$$a10.1038/sj.bmt.1705758$$p709 -$$tBone Marrow Transplant$$uBatts ED, Lazarus HM . Diagnosis and treatment of transplantation-associated thrombotic microangiopathy: real progress or are we still waiting? Bone Marrow Transplant 2007; 40: 709–719.$$v40$$y2007
000129194 999C5 $$1S Jodele$$2Crossref$$9-- missing cx lookup --$$a10.1182/blood-2014-03-564997$$p645 -$$tBlood$$uJodele S, Davies SM, Lane A, Khoury J, Dandoy C, Goebel J et al. Diagnostic and risk criteria for HSCT-associated thrombotic microangiopathy: a study in children and young adults. Blood 2014; 124: 645–653.$$v124$$y2014
000129194 999C5 $$1S Ito$$2Crossref$$9-- missing cx lookup --$$a10.1182/blood-2014-11-611780$$p10 -$$tBlood$$uIto S, Barrett AJ . ST2: the biomarker at the heart of GVHD severity. Blood 2015; 125: 10–11.$$v125$$y2015
000129194 999C5 $$1AM Miller$$2Crossref$$9-- missing cx lookup --$$a10.1084/jem.20071868$$p339 -$$tJ Exp Med$$uMiller AM, Xu D, Asquith DL, Denby L, Li Y, Sattar N et al. IL-33 reduces the development of atherosclerosis. J Exp Med 2008; 205: 339–346.$$v205$$y2008
000129194 999C5 $$1J Sánchez-Más$$2Crossref$$9-- missing cx lookup --$$a10.1111/eci.12282$$p643 -$$tEur J Clin Invest$$uSánchez-Más J, Lax A, Asensio-López Mdel C, Fernandez-Del Palacio MJ, Caballero L, Santarelli G et al. Modulation of IL-33/ST2 system in postinfarction heart failure: correlation with cardiac remodelling markers. Eur J Clin Invest 2014; 44: 643–651.$$v44$$y2014
000129194 999C5 $$1EE Coglianese$$2Crossref$$9-- missing cx lookup --$$a10.1373/clinchem.2012.192153$$p1673 -$$tClin Chem$$uCoglianese EE, Larson MG, Vasan RS, Ho JE, Ghorbani A, McCabe EL et al. Distribution and clinical correlates of the interleukin receptor family member soluble ST2 in the Framingham Heart Study. Clin Chem 2012; 58: 1673–1681.$$v58$$y2012
000129194 999C5 $$1TJ Wang$$2Crossref$$9-- missing cx lookup --$$a10.1161/CIRCULATIONAHA.112.129437$$p1596 -$$tCirculation$$uWang TJ, Wollert KC, Larson MG, Coglianese E, McCabe EL, Cheng S et al. Prognostic utility of novel biomarkers of cardiovascular stress: the Framingham Heart Study. Circulation 2012; 126: 1596–1604.$$v126$$y2012
000129194 999C5 $$1J Bartunek$$2Crossref$$9-- missing cx lookup --$$a10.1016/j.jacc.2008.09.027$$p2166 -$$tJ Am Coll Cardiol$$uBartunek J, Delrue L, Van Durme F, Muller O, Casselman F, De Wiest B et al. Nonmyocardial production of ST2 protein in human hypertrophy and failure is related to diastolic load. J Am Coll Cardiol 2008; 52: 2166–2174.$$v52$$y2008
000129194 999C5 $$1DM Ponce$$2Crossref$$9-- missing cx lookup --$$a10.1182/blood-2014-06-584789$$p199 -$$tBlood$$uPonce DM, Hilden P, Mumaw C, Devlin SM, Lubin M, Giralt S et al. High day 28 ST2 levels predict for acute graft-versus-host disease and transplant-related mortality after cord blood transplantation. Blood 2015; 125: 199–205.$$v125$$y2015
000129194 999C5 $$1B Kwak$$2Crossref$$9-- missing cx lookup --$$a10.1038/82219$$p1399 -$$tNat Med$$uKwak B, Mulhaupt F, Myit S, Mach F . Statins as a newly recognized type of immunomodulator. Nat Med 2000; 6: 1399–1402.$$v6$$y2000
000129194 999C5 $$1PM Ridker$$2Crossref$$9-- missing cx lookup --$$a10.1161/01.CIR.100.3.230$$p230 -$$tCirculation$$uRidker PM, Rifai N, Pfeffer MA, Sacks F, Braunwald E . Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators. Circulation 1999; 100: 230–235.$$v100$$y1999
000129194 999C5 $$1H Amuro$$2Crossref$$uAmuro H, Ito T, Miyamoto R, Sugimoto H, Torii Y, Son Y et al. Statins, inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase, function as inhibitors of cellular and molecular components involved in type I interferon production. Arthritis Rheum 2010; 62: 2073–2085.$$y2010
000129194 999C5 $$1K Sato$$2Crossref$$9-- missing cx lookup --$$a10.1016/j.atherosclerosis.2010.03.034$$p33 -$$tAtherosclerosis$$uSato K, Nuki T, Gomita K, Weyand CM, Hagiwara N . Statins reduce endothelial cell apoptosis via inhibition of TRAIL expression on activated CD4 T cells in acute coronary syndrome. Atherosclerosis 2010; 213: 33–39.$$v213$$y2010
000129194 999C5 $$1CY Wang$$2Crossref$$9-- missing cx lookup --$$a10.1016/j.molmed.2007.11.004$$p37 -$$tTrends Mol Med$$uWang CY, Liu PY, Liao JK . Pleiotropic effects of statin therapy: molecular mechanisms and clinical results. Trends Mol Med 2008; 14: 37–44.$$v14$$y2008
000129194 999C5 $$1RG Casey$$2Crossref$$9-- missing cx lookup --$$a10.1016/j.jss.2004.08.001$$p176 -$$tJ Surg Res$$uCasey RG, Joyce M, Roche-Nagle G, Chen G, Bouchier-Hayes D . Pravastatin modulates early diabetic nephropathy in an experimental model of diabetic renal disease. J Surg Res 2005; 123: 176–181.$$v123$$y2005
000129194 999C5 $$1M Úriz$$2Crossref$$9-- missing cx lookup --$$a10.1371/journal.pone.0028717$$pe28717 -$$tPLoS ONE$$uÚriz M, Sáez E, Prieto J, Medina JF, Banales JM . Ursodeoxycholic acid is conjugated with taurine to promote secretin-stimulated biliary hydrocholeresis in the normal rat. PLoS ONE 2011; 6: e28717.$$v6$$y2011
000129194 999C5 $$1T Ruutu$$2Crossref$$9-- missing cx lookup --$$a10.1016/j.bbmt.2013.10.014$$p135 -$$tBiol Blood Marrow Transplant$$uRuutu T, Juvonen E, Remberger M, Remes K, Volin L, Mattsson J et al. Improved survival with ursodeoxycholic acid prophylaxis in allogeneic stem cell transplantation: long-term follow-up of a randomized study. Biol Blood Marrow Transplant 2014; 20: 135–138.$$v20$$y2014